Hope for alopecia patients? Lilly’s baricitinib delivers significant hair regrowth in adolescents
Eli Lilly and Company (Lilly), in collaboration with Incyte, has reported significant progress in the treatment of severe alopecia areata with its JAK inhibitor, baricitinib ... Read More
Lilly’s Jaypirca moves closer to European approval for relapsed chronic lymphocytic leukemia
Eli Lilly and Company (Lilly) has moved one step closer to securing European approval for its targeted blood cancer therapy, Jaypirca (pirtobrutinib), after the European ... Read More
Inside Lilly’s $50bn push to transform American drug production
Eli Lilly and Company (Lilly) has unveiled an ambitious plan to more than double its U.S. manufacturing investment, committing over $50 billion since 2020. This ... Read More
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay patients seeking obesity medications. The company’s latest ... Read More
Eli Lilly acquires Organovo’s FXR program to advance IBD drug development
In a significant industry development, Eli Lilly and Company has acquired Organovo Holdings, Inc.’s FXR program, including its lead drug candidate FXR314, marking a major ... Read More
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion, marking a 32% increase from the previous ... Read More
Eli Lilly acquires promising PI3Kα inhibitor from Scorpion Therapeutics
Eli Lilly and Company (Lilly) has announced a significant acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program, a move poised to enhance its oncology portfolio. ... Read More
Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial
Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), for ... Read More
Lilly commits $3bn to Wisconsin facility to boost injectable medicine production
Eli Lilly and Company (Lilly) has unveiled plans for a $3 billion expansion of its newly acquired manufacturing facility in Kenosha County, Wisconsin, signalling a ... Read More
Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape
Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader ... Read More